In a clinical trial in patients with stage IV melanoma treated with DCs loaded with a multi-peptide (WT1, gp100, tyrosinase, and MAG-E3 or MAGE-A2) combined with paclitaxel (175 mg/m) and carboplatin (area under the curve 5), an OS of up to 24 months was observed.124. This evidence concerns the gene MAGEA3 and melanoma.